45 participants
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-09-25
- Start Date:
- 2025-11-01
- Completion:
- 2026-07-01
Conditions
- NSCLC (Non-small Cell Lung Cancer)
Interventions
- DRUG
No Results Yet